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Background: The Metabolic Syndrome is the clustering of several cardiovascular risk 
factors for coronary heart disease and Type 2 Diabetes Mellitus.  This syndrome is of 
public health importance due to its high prevalence and high correlation to all-cause, 
CHD, and CVD mortality.  The purpose of the current study was to determine if a change 
in aerobic fitness in the treatment group significantly decreased the odds of Metabolic 
Syndrome at 6 and 18 months. 
Methods: There were 810 adult participants in this trial with above-optimal blood 
pressure and up to stage I hypertension.  Participants were part of an advice-only control 




Results: A change in aerobic fitness, independent of treatment status, was significantly 
associated with a decrease in prevalent Metabolic Syndrome at both 6 and 18 months 
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The Metabolic Syndrome is the clustering of several cardiovascular risk factors 
for coronary heart disease (CHD) and Type 2 Diabetes Mellitus (DM) (Eckel,Grundy, 
and Zimmet, 2005).  Instead of one definite definition, there are three commonly used 
definitions of this syndrome.  All three include the presence of at least three 
cardiovascular risk factors; however, all of the definitions differ in the specific risk 
factors that are necessary to be present in order to be classified as having the Metabolic 
Syndrome.  The first definition to be utilized was created by the World Health 
Organization (WHO), followed by the National Cholesterol Education Program (NCEP), 
and finally the International Diabetes Federation (IDF) (Eckel et al, 2005).  Table 1 
provides a breakdown of all three definitions.    
Table 1 Definitions of the Metabolic Syndrome 
WHO 1999 NCEP 2001 IDF 
Diabetes or impaired 
glucose tolerance or insulin 
resistance* PLUS 2 or more 
of the following: 
Three or more of the 
following: 
Central obesity: waist 
circumference > 102 cm 
(M), > 88 cm (F) 
Central obesity: waist 
circumference, ethnicity 
specific; for Europeans and 
Africans, >93 cm (M), >79 
cm (F) PLUS 2 or more of 
the following: 
Obesity: BMI>30kg/m2 or 
WHR > 0.9 (M) > 0.85 (F) 
Hypertriglyceridaemia: 
Triglycerides > 149 mg/dl 
Raised triglycerides: >149 
mg/dl   
Dyslipidemia: Triglycerides 
> 149 mg/dl or HDL-C < 35 
mg/dl (M), < 39 mg/dl (F) 
Low HDL-C: < 40 mg/dl 
(M), < 50 mg/dl (F) 
Reduced HDL-cholesterol: 
<40 mg/dl (M), <50 mg/dl 
(F) 
Hypertension: Blood 
pressure >139/89 mmHg or 
medication 
Hypertension: Blood 
pressure > 129/84 mmHg or 
medication 
Raised Blood pressure: 
systolic>129 mmHg or 
Diastolic> 84mmHg or 
treatment 
Microalbuminuria: Albumin 
excretion > 19 ug/min or 
albumin:creatinine ratio > 
29 mg/g 
Fasting glucose > 109 mg/dl Raised fasting plasma 
glucose: Fasting plasma 
glucose >99mg/dl or type 2 
diabetes 
*defined as the top quartile of fasting insulin in the non-diabetic population. 





  According to the most recent data from the Third National Health and Nutrition 
Examination Survey (NHANES III), the unadjusted prevalence of the metabolic 
syndrome in the US is approximately 35% using the NCEP definition and 39% using the 
IDF definition (Ford, 2005).  This slight discrepancy can be explained by the variations in 
the definitions.  (See table 1 for details).  Prevalence of the Metabolic Syndrome is 
especially high among African Americans (Carnethon, Catherine, Hill, Sidney, Savage, 
and Liu, 2004; Eckel et al, 2005).  Although it is difficult to compare studies with so 
many definitions in use (Zimmet et al, 2004; Eckel et al, 2005), the Metabolic Syndrome 
has recently become of importance to epidemiologists due to its high prevalence (Zimmet 
et al, 2004; Ford, 2005; Grundy, 2005; Ford et al, 2006) and high correlation to all-cause, 
coronary heart disease (CHD) and cardiovascular disease (CVD) mortality, regardless of 
the definition used (Isommaa, Almgren, Tuomi, Forsen, Lahti, Nissen, Taskinen, and 
Groop, 2001; Malik et al., 2004; Lakka, Laaksonen, Lakka, Niskanen, Kumpusalo, 
Tuomilehto, and Salonen, 2004; Hu, Qiao, Tuomilehto, Balkau, Borch-Johnsen, and 
Pyorala, 2004).  Table 2 provides a breakdown of the odds ratios of mortality from 
Metabolic Syndrome by definition.  
 
Table 2 









Issomma et al., 
2001 
WHO 3.0  2.0  
Malik et al., 2004 NCEP 2.0   
Lakka et al., 2002 WHO  2.6 – 3.0  2.0  





Hypertension plays an important role in the Metabolic Syndrome.  Hypertension 
and obesity are the two most common risk factors found in those with the Metabolic 
Syndrome (Isommaa et al, 2001).  Patients with hypertension have greater than a two-
fold increase in the prevalence of the Metabolic Syndrome than those without (Ford, 
2005).  This could be due to the correlation of insulin resistance with the Metabolic 
Syndrome (Zimmet et al., 2004).  There is some evidence that hypertension itself is an 
insulin resistant state (Ferrannini, Buzzigoli, Bonadnna, Giorico, Oleggini, Graziadei, 
Pedrinelli, Brandi, and Bevilacqua, 1987).  Hypertensive subjects show significantly 
greater insulin resistance.  Furthermore, it is suggested that hyperinsulinemia functions as 
a compensatory mechanism for insulin resistance in persons with hypertension 
(Ferrannini et al, 1987).  These two mechanisms show the correlation of hypertension and 
insulin resistance, linking hypertension with the Metabolic Syndrome. 
The prevalence of the Metabolic Syndrome is greater among African Americans.  
Importantly, it is also well documented that the prevalence of hypertension (Thomas, 
Semenya, Thomas, Thomas, Neser, Pearson, and Gillum, 1987; Jamerson, 1993; Burt, 
Whelton, Roccella, Brown, Cutler, Higgins, Horan, and Labarthe, 1995; Branson, Davis, 
and Butler, 2005), as well as insulin resistance (Reiner, Carison, Ziv, Iribarren, Jaquish, 
and Nerickerson, 2007), is also greater among African Americans.  While it was once 
thought that cultural differences were the sole reason for the discrepancy in the racial 
prevalence of these cardiovascular risk factors, there is now some research that suggests 
that physiological differences between African Americans and non-African Americans 




al, 1987; Jamerson, 1993; Cardillo, Kilcoyne, Cannon, and Panza, 1998; Mall, Wagoner, 
Levin, Kardia, and Liggett, 2002; Branson et al, 2005).   
It is well documented in cross sectional studies that physical activity (Rennie, 
McCarthy, Yazdgerdi, Marmot, and Brunner, 2003; Franks, Ekelund, Brage, Wong, and 
Wareham, 2004; Ford, Kohl, Mokdad, Ajani, 2005) and increased physical fitness have a 
preventive or protective effect on the Metabolic Syndrome (Kullo, Hensrud, and Allison, 
2002; Farrell, Cheng, and Blair, 2004; Lee, Kuk, Katzmarzyk, Blair, Church, and Ross, 
2005).  It is also documented in some cross sectional studies that both physical activity 
and aerobic fitness have an inverse relationship to the Metabolic Syndrome independent 
of one another (Wareham, Hennings, Byrne, Hales, Prentice, and Day, 1998; Carroll, 
Cooke, and Butterly, 2000; Irwin, Ainsworth, Mayer-Davis, Addy, Pate, and Durstine, 
2002).  However, these studies are limited by their cross sectional nature, small sample 
sizes, and/or lack of an African American sample.   
There are six longitudinal studies showing the preventive effect of fitness on the 
Metabolic Syndrome (Laaksonen, Lakka, Salonen, Niskanen, Rauramaa, and Lakka, 
2002; Carnethon, Gidding, Nehgme, Sidney, Jacobs, and Liu, 2003; Palaniappan, 
Carnethon, Wang, Hanley, Fortmann, Haffner, and Wagenknecht, 2004; Ekelund, Brage, 
Franks, Hennings, Emms, and Wareham, 2005; LaMonte, Barlow, Jurca, R., Kampert, 
Church, and Blair, 2005).  However, these studies are limited by homogeneous samples 
that were either all middle aged non-African American men or non-African American 
men and women.  Only one of these studies included African Americans in the sample 
(Palaniappan et al, 2004).  Five of the six studies agree that there is a protective value of 




Ekelund et al, 2005; LaMonet et al, 2005).  The last study found no relationship between 
physical activity and the incidence of the Metabolic Syndrome (Palaniappan et al, 2004).  
Interestingly, this was the only study including African Americans.  In one study of 
physical activity and aerobic fitness, those who were the least fit and the most sedentary 
had a seven fold risk increase of developing the Metabolic Syndrome over a four year 
follow up (Laaksonen et al, 2002).  These cross sectional and longitudinal results give 
rise to the plausibility that an aerobic fitness intervention should have a protective effect 
on those subjects without baseline Metabolic Syndrome and a therapeutic effect on those 
with the Metabolic Syndrome at baseline. 
The results from several exercise intervention studies agree with the positive 
results found in the cross sectional and longitudinal studies.  These results all show that 
with an increase in exercise, some subjects with baseline Metabolic Syndrome can 
improve their health significantly enough that they are no longer classified as having the 
Metabolic Syndrome at follow up (Milani and Lavie, 2003; Katzmarzyk, Leon, Wilmore, 
Skinner, Rao, Rankiknen, and Bouchard, 2003; Shubair, Kdis, McKelvie, Arthur, and 
Sharma, 2004; Stewart, Bacher, Turner, Lim, Hees, Shapiro, Tayback, and Ouyang, 
2005).  Although the results of these studies are encouraging, only one of the 
interventions was a randomized controlled trial (Stewart et al, 2005).  Unfortunately, this 
study was limited to 115 total subjects, only 1% being African American.  As previously 
mentioned, it is important to include African Americans in research because they may 
differ physiologically and culturally from non-African Americans.  Subjects in this study 
increased their fitness, measured by VO2max, by 16% compared to controls.  There was a 




reach statistical significance (P<.06) (Stewart et al., 2005). Other intervention studies had 
significantly more subjects, but lacked a control group.  In the HERITAGE family study, 
there were 621 subjects, of which 192 were African American (Katzmarzyk et al., 2003).  
At baseline, 16.9% of the participants had the Metabolic Syndrome.  After a 20 week 
aerobic exercise program, only 11.8% of those subjects maintained prevalence, which 
was a statistically significant reduction.  Unfortunately, there was no control group for 
comparison (Katzmarzyk et al., 2003).   The last two intervention studies were both 
performed with cardiac rehabilitation patients, and thus already had known Coronary 
Heart Disease (CHD).  Although both studies did show a significant reduction in the 
prevalence of Metabolic Syndrome after an exercise intervention, one did not have a 
control group (Shubair et al, 2004) and the other had a control group that consisted of 
participants who had agreed to be a control after dropping out of the intervention group 
(Milani et al, 2003).  Because both studies were done on cardiac rehabilitation patients, 
the results are limited in their generalizability. 
As previously mentioned, there is some research suggesting that the differences in 
African Americans and non-African Americans make it important to over sample for 
African Americans, as they may have both physiological and cultural differences than 
non-African Americans.  There is a different pattern of hemodynamic reactivity in 
African Americans and Non-African Americans; African Americans have higher 
peripheral resistance and a lower cardiac output than their non-African American 
counterparts (Cardillo et al, 1998).  They also have greater circulatory hyperactivity, 
which can be defined as higher systolic and diastolic blood pressures, as well as heart 




significantly greater even when resting blood pressure is accounted for (Thomas et al, 
1987).   
Although the previously mentioned studies show the physiological reasons for the 
increase in hypertension in African Americans, there is also data that show the difference 
may be cultural.  In the Coronary Artery Risk Development in Young Adults (CARDIA) 
study, it was shown that there were no significant genetic differences between African 
Americans and Non-African Americans, suggesting that the differences may be cultural 
(Reiner et al, 2007).  In the CARDIA study, higher education level, used as a proxy for 
social economic status (SES),  was associated with increased risk factors of the Metabolic 
Syndrome, specifically, increased waist circumference, hypertension, and risk of pre-
diabetes in African Americans.  These risks were independent of genetic ancestry.  
Because there are data implicating both cultural and physiological differences in African 
Americans and non-African Americans contributing to the increased risk in African 
Americans for Metabolic Syndrome, it is important not to rule out any possible 
differences, and treat African Americans as their own sub-population.   
Not only are African Americans more prone to cardiovascular risk factors, they 
also may respond differently than do whites to treatments for these risk factors 
(Jamerson, 1993; Sacks, Svetkey, Vollmer, Lawrence, Appel, Bray, Harsha, Obarzanek, 
Conlin, Miller, Simons-Morton, Karanja, and Pao-Hwa, 2001; Branson et al, 2005; Rao, 
Manjula, and Mayo, 2007).  During a dietary intervention using the DASH diet, African 
Americans responded more positively to sodium reduction as both treatment and 
prevention of hypertension than did whites (Sacks et al, 2001).   Although there is the 




African Americans, it is doubtful that the underlying root of these differences is due to 
retention issues because in some of the treatments, such as sodium reduction, the African 
American participants have a more positive treatment effect than the non-African 
American participants (Sacks et al, 2001).  Because African Americans may have a 
different disease etiology than non-African Americans, and they also may respond 
differently to dietary treatments, it is logical to question if they will respond differently to 
physical activity and increased fitness as a treatment for hypertension and insulin 
resistance, and subsequently, the Metabolic Syndrome.  Whether the differences are 
cultural or physiological, using a randomized controlled trial including a high percentage 
of African Americans, such as the PREMIER trial, for a secondary analysis on the 
Metabolic Syndrome will be an important contribution to the literature as well as to 
public health. 
According to a recent review conducted by Ford and Li (2006), there are no 
rigorous randomized controlled trials examining the effect of physical activity and 
increasing physical fitness on the Metabolic Syndrome with sufficient sample size and 
generalizability to the larger population.  According to another review by Branson et al 
(2005), under-representation of African Americans is a common problem that jeopardizes 
the generalizability of results to the entire population.  It is further stated that the health 
of African Americans as a population depends upon this under-representation being 
recognized, and that specific interventions be planned and implemented.  Therefore, the 
purpose of the present study was to test the significance of the change in aerobic fitness 
from the subjects of the PREMIER study as it relates to a change in the Metabolic 




addition to the literature on the Metabolic Syndrome because it addresses both of the 
issues in the two review articles discussed above.  One third of the study participants in 
this data set are African American.  Additionally, PREMIER is a randomized controlled 
trial (RCT).  Randomized Controlled Trials are currently the ‘gold standard’ in research.  
In brief, participants were randomly recruited from four different locations and grouped 
into cohorts.  They underwent one of three conditions, established guidelines, established 
guidelines plus the DASH diet, or an advice-only control condition.  Briefly, the 
established guidelines group attended group and individual intervention sessions with 
goals to increase physical activity and follow dietary guidelines set forth by JNC V.  The 
established guidelines plus DASH diet group attended intervention sessions with the 
same physical activity guidelines, but also had information about the DASH diet.  The 
participants in the advice-only control group attended only 2 intervention sessions, and 
were told to increase physical activity and follow the food guide pyramid, but were not 
given any specific guidelines for either element.  (See Table 6 for the specific details of 
the intervention groups).  Measurements of all Metabolic Syndrome criteria were taken at 
baseline, a 6 month follow-up, and an 18 month follow-up (Funk, Elmer, Stevens, 
Harsha, Craddick, Lin, Young, Champagne, Brantley, McCarron, Simons-Morton, and 
Appel, 2006).  For further detail on this procedure, refer to the Methods section.  For this 
paper, the NCEP definition of the Metabolic Syndrome will be analyzed so that the 
results may be compared to the most recent past studies as well as to any future studies 







1. Change in fitness from the two intervention groups (combined for this paper), will 
be associated with reduced prevalence of Metabolic Syndrome compared with the 
advice only group.  This difference is expected to be the most pronounced from 
baseline to the 6 month follow up.  The difference between baseline and the 18 
month follow up is expected to be significant, but to a lesser degree than the 6 
month difference due to slightly poorer adherence to the intervention between 6 
and 18 months.   
2. The change in fitness in African Americans will be associated with a lesser, albeit 
still significant, reduction in Metabolic Syndrome when compared to their non-




All participants are from the PREMIER trial.  All were recruited by mass 
mailings, advertisements, and news stories.  African Americans were over-recruited 
(Funk et al., 2006).  There were originally 3964 individuals who came to three 
screenings.  Of these 3964, 3154 were ineligible due to blood pressure being too low 
(2103), blood pressure being too high (194), or other exclusions as described below (857) 
(Writing Group of PREMIER, 2003).  The final cohort consisted of 810 adults who were 
at least 25 years of age.  The participants are 62% women and 34% African Americans.  
See figure 1 for a complete participant flow chart.  See table 3 for a complete list of 




 Participants are from one of four participating clinical settings including Johns 
Hopkins University, Baltimore, MD; Pennington Biomedical Research Center, Baton 
Rouge, La; Duke University Medical Center, Durham, NC; and Kaiser Permanente 
Center for Health Research, Portland, Ore (Writing Group of PREMIER, 2003).   In order 
to be included in the study, all inclusion and exclusion criteria had to be met.  The major 
components of these criteria are as follows: All participants are at least 25 years of age.  
All participants have above optimal blood pressure, including anyone with up to stage 1 
hypertension according to JNC VI (Writing Group of PREMIER, 2003).  All participants 
have a body mass index (BMI) ranging from 18.5 -45 kg/m2.  Other inclusion criteria 
were to be willing and able to participate in all aspects of the intervention, provide 
informed consent, and access to a telephone.  Major exclusion criterion were for 
medications, medical history, pregnancy, psychiatric disabilities, and major body weight 
changes in the 3 months prior to screening (Svetkey, Harsha, Vollmer, Stevens, 
Obarzanek, Elmer, Pao-Hwa, Champagne, Simons-Morton, Aickin, Proschan, and Appel, 

















           194 BP Too High 
         2103 BP Too Low 
           857 Other Exclusions 
810 Randomized
268 Assigned to Established 
Intervention Group 
  6-Month Assessment 
   253 BP Measurement 
   251 Weight 
   220 24-h Urine 
   229 Fitness Test 
   233 Dietary Recall 
   233 Physical Activity 
   242 Blood Sample 
3 Month Assessment 
250 Had BP Measurements 
268 Included in Primary 
Analyses of Blood Pressure 
269 Assigned to Established 
+ DASH Intervention Group 
   6-Month Assessment 
   253 BP Measurement 
   249 Weight 
   223 24-h Urine 
   238 Fitness Test 
   236 Dietary Recall 
   239 Physical Activity 
   249 Blood Sample 
3 Month Assessment 
252 Had BP Measurements 
269 Included in Primary 
Analyses of Blood Pressure 
273 Assigned to Advice Only 
Group 
   6-Month Assessment 
   259 BP Measurement 
   256 Weight 
   219 24-h Urine 
   236 Fitness Test 
   243 Dietary Recall 
   242 Physical Activity 
   253 Blood Sample 
3 Month Assessment 
250 Had BP Measurements 
273 Included in Primary 
Analyses of Blood Pressure 
BP Indicates blood pressure; DASH, Dietary Approaches to Stop Hypertension. 














Baseline Characteristics by Randomized Group1 
Characteristic Advice only
(n = 273) 
Established
(n = 268) 
Established + 
DASH 
(n = 269) 
Age, mean (SD), y 49.5 (8.8) 50.2 (8.6) 50.2 (9.3) 
Female 172 (63.0) 174 (64.9) 154 (57.2) 
Race or ethnicity    
    African American 100 (36.6) 100 (37.3) 79 (29.4) 
    Non-Hispanic white 167 (61.2) 163 (60.8) 181 (67.3) 
    All others 6 (2.2) 5 (1.9) 9 (3.3) 
BMI, mean (SD)2 32.9 (5.6) 33.0 (5.5) 33.3 (6.3 
Weight classification    
    Non-overweight (BMI, 
,25) 
15 (5.5) 13 (4.9) 16 (6.0) 
    Overweight (BMI, 25-
29.9) 
76 (27.8) 80 (29.9) 82 (30.5) 
    Obese (BMI, >30) 182 (66.7) 217 (81.0) 224 (83.6) 
Alcohol, mean (SD), 
drinks/d 
0.21 (0.41) 0.24 (0.47)  0.29 (0.52) 
Sedentary (kcal/kg/d <35) 223 (81.7) 217 (81.0) 224 (83.6) 
Annual household income    
    <$30,000 31 (11.4) 26 (9.7) 27 (10.0) 
    $30,000-$60,000 91 (33.3) 83 (31.0) 82 (30.5) 
    > $60,000 142 (52.0) 151 (56.3) 148 (55.0) 
    Unknown (no answer) 9 (3.3) 8 (3.0) 12 (4.5) 
Education    
    High school or less 21 (7.7) 20 (7.5) 33 (12.3) 
    Some college 175 (64.1) 157 (58.6) 144 (53.5) 
    Some graduate school 77 (28.2) 91 (34.0) 92 (34.2) 
Current cigarette smokers 14 (5.1) 18 (6.7) 7 (2.6) 
Dyslipidemia3 59 (21.6) 68 (25.4) 64 (23.8) 
Blood pressure, mean (SD), mm Hg 
    Systolic 134.2 (10.1) 135.5 (9.2) 134.9 (9.4) 
    Diastolic 84.8 (4.3) 85.0 (4.1) 84.6 (4.0) 
Hypertensive 104 (38.1) 100 (37.3) 100 (37.2) 
Total Participants (n) 
    Metabolic Syndrome 399   
    No Metabolic Syndrome 397   
Abbreviations: BMI, body mass index; DASH, Dietary Approaches to Stop Hypertension. 
1 Data are presented as No. (%) unless otherwise indicated 
2 Body mass index is calculated as weight in kilograms divided by the square of the height in meters. 
3 Total cholesterol >240 mg/dL (6.21 mmol/L) and/or use of lipid-lowering medication. 
 








 Baseline SBP 120-159 mmHg and DBP 80-95 mmHg 
 Age 25 or older 
 BMI 18.5-45 kg/m2 
 Willing and able to participate fully in all aspects of the intervention 
 Informed consent 
 Access to telephone 
Medication Exclusions 
 Regular use of anti-hypertensive drugs or other drugs that raise or lower BP 
 Current use of insulin or oral hypoglycemic agents 
 Current use of medications for treatment of psychosis or manic-depressive illness 
 Use of weight-loss medications in the three months prior to first screening visit 
Medical History Exclusions 
 Cardiovascular event 
 Congestive heart failure 
 Current symptoms of angina or peripheral vascular disease 
 Cancer diagnosis (except for non-melanoma skin cancer) or treatment in past two 
years 
 Renal insufficiency (GFR < 60 ml/min as estimated using Crokroft-Gault formula) 
 Random glucose > 160 mg/dL or Fasting Blood Sugar > 126 mg/dL 
 Psychiatric hospitalization within the last two years 
Other Exclusions 
 Inability to provide acceptable BP measurements 
 Consumption of more than 21 alcoholic drinks per week or binge drinking 
 Planning to leave the area prior to the anticipated end of participation 
 Body weight change > 15 pounds in the three months prior to first screening visit 
 Pregnant, breast feeding, or planning pregnancy prior to the end of participation 
 Current participation in another clinical trial 
 Investigator discretion for safety or adherence reasons 
 Household member of another PREMIER participant or of a PREMIER staff 
member 
* Table adapted from Svetkey et al, 2003 
 
Study Design 
All participants were randomly assigned by a computer program.  Assignments 
were stratified by clinic and hypertension status; randomization block size was 24 
(Writing Group of PREMIER, 2003).  Participants were randomly assigned to one of 




termed the Established Diet Group, or a comprehensive intervention plus DASH diet 
group, termed the Established Group plus DASH Diet (Funk et al, 2006).  The control 
group participants followed recommendations set forth by the National High Blood 
Pressure Education Program (NHBPEP) for patients with above optimal blood pressure 
and stage 1 hypertension (Funk et al, 2006).  The recommendations include weight loss if 
overweight, limiting alcohol and dietary sodium intake, regular physical activity, and 
eating a healthful diet.  Written materials were provided at a baseline visit and again at 
the six-month follow up visit.  No behavioral counseling was provided (Funk et al, 2006).    
 The comprehensive lifestyle intervention and the comprehensive lifestyle plus 
DASH diet groups received a multi-component lifestyle intervention program based on 
the most current clinical practice guidelines for blood pressure control and cardiovascular 
health (Svetkey et al, 2003).  The specific guidelines were as follows: (1) weight loss of 
at least 15lbs (6.8 kg) at six months for those with a BMI of at least 25, (2) at least 180 
minutes per week of moderate intensity physical activity, (3) daily intake of no more than 
100 mEq of dietary sodium, and (4) daily intake of 1 oz or less of alcohol (Writing Group 
of PREMIER, 2003).  See table 6 for full detail of the intervention groups.   The 
comprehensive lifestyle plus DASH diet group was instructed on how to properly eat 
according to the DASH diet.  The most emphasized aspects of the DASH diet in the 
PREMIER trial were eating 9 to 12 servings of fruits and vegetables and 2 to 3 servings 
of low-fat dairy products per day while limiting fat intake to less than 25% of total kcals.  
Saturated fat was also to be reduced to less than 10% (Funk et al, 2006).  For original 
DASH diet requirements, see table 5.  Although the dietary component for the two 




schedules regarding physical activity, sodium intake, and weight loss.  Therefore, for the 
purpose of this paper, the two intervention groups were combined into one intervention 
group.  The follow-up values of each individual part of the DASH diet were co-varied for 
in a logistic regression in order to isolate the effects of the change in aerobic fitness 
within the combined treatment group.  Refer to the statistical analysis for details. 
The intervention schedules for the two intervention groups were identical (Funk et 
al, 2006).  During the initial six months, there were 18 face to face intervention contacts, 
(14 were group meetings and 4 were individual).  Group sessions were approximately 1.5 
to 2 hours in duration.  They were interactive and dealt mostly with problem solving, 
support, and program ownership.  They included four components, (1) taste it!, (2) 
progress check, (3) try it!, and (4) next steps.  The taste it! section allowed participants to 
be introduced to new foods, recipes, and products that met the study dietary targets.  The 
progress check was a discussion aiming to encourage exploration of supportive 
behavioral strategies. The goal of try it! was to allow for small-group activities that 
reinforced social support and physical activity.  Finally, the next steps portion was used 
as a time for participants to draft plans and goals for the upcoming weeks.  Physical 
activity diaries were kept and used as feedback at these sessions (Funk et al, 2006).   
 The main outcome results were published in 2003.  The investigators found that 
lifestyle changes can significantly reduce blood pressure and risk of cardiovascular 
disease in persons with above optimal blood pressure (Writing Group of PREMIER, 
2003).  The reduced blood pressure and cardiovascular disease risk were significant in 
African Americans and non-African Americans.  However, the lifestyle changes had a 




investigators studied the effects of the individual intervention components and SBP for 
participants having or not having Metabolic Syndrome.  They found that presence of 
Metabolic Syndrome attenuated the SBP reduction in the established group, but that the 
attenuation was overcome in the Established plus DASH diet group (Lien, F. L., Brown, 
A. J., Ard, J. D, Loria, C., Erlinger, T. P., Feldstein, A. C, Lin, P., Champagne, C. M., 
King, A. C., McGuire, H. L., Stevens, V. J., Brantley, P. J., Harsha, D. W., McBurnie, M. 
A., Appel, L. J., and Svetkey, L. P., 2007).   
Table 5 
Original DASH Dietary Pattern Targets for Nutrient 
Amounts and Servings From Food Groups (at the 2100 
kcal level: Appel et al., 1997) 
Nutrients Nutrient Amount 
Total fat. % kcal 27 
Saturated fat. % kcal 6 
Protein. % kcal 18 
Carbohydrate. % kcal 55 
Fiber. g 31 
Potassium. mg 4700 
Magnesium. mg 500 
Calcium. mg 1240 
Food Groups Servings/Day 
Vegetables 4 to 5 
Fruit 4 to 5 
Low-fat or fat-free dairy foods 2 to 3 
Lean meats, poultry, and fish < 2 
Grains, and grain products 7 to 8 
Nuts, seeds, and dry beans 4 to 5/week 
Fats and oilsa 2 to 3 
Sweets (added sugars)b 5/week 
NOTE: DASH = Dietary Approaches to Stop Hypertension 
(Appel et al., 1997). 
a. Margarine, low-fat mayonnaise, or salad dressing, vegetable 
oils. 
b. Sugar, jelly, jam, syrups, sorbets, ices. 
 







Intervention Lifestyle Targets and Delivery Approaches for PREMIER Treatment Groups 
 Established 
Guidelines (EG) 
EG + DASH Advice Only 
Comparison 
Lifestyle Targets  Goals  
Physical Activity/week 180 min. 180 min. Increase 
Weight lossa > 15 lb > 15 lb As needed 
Total calories/day Individual targetb Individual targetb No target 
Sodium/day < 2400 mg < 2400 mg Reduce 
Alcohol/day < 1 oz. Men. < 1 oz. Men. < 1 oz. Men. 
 < .5 oz. Women. < .5 oz. Women. < .5 oz. Women. 
Dietary focus JNC V DASH FGP 
   % kcal fat < 30% < 25% FGP 
   % kcal saturated fat < 10% < 7% FGP 
   F&V servings Not emphasized 9 to 12 servingsc FGP 
   Low-fat dairy servings Not emphasized 2 to 3 servingsc FGP 
Recommended Self-
Monitoring 
Yes Yes None 
   # of days/week > 3 > 3 None 
   Lifestyle targets monitored Calories, Na, PA Calories, Na, PA, 




Description   
Approach Intensive 
behavioral     
  program with     
  extensive self- 




  program with  
  extensive self- 
  monitoring and 
ME 
Advice only 
Total # of sessions    
   Individual 7 7 2 
   Group 26 26 0 
NOTE: JNC V = The Fifth Report of the Joint National Committee on Detection, Evaluation, 
and Treatment of High Blood Pressure (National Institutes of Health. 1992): DASH = Dietary 
Approaches to Stop Hypertension (Appel et al., 1997): FGP = Food Guide Pyramid (U.S. 
Department of Health and Human Services & U.S. Department of Agriculture. 2000): Na = 
Sodium: PA = Physical Activity: F&V = fruits & vegetables: ME = motivational enhancement 
a. Weight loss for those with body mass index < 25. 
b. Individual target set for caloric intake to achieve weight loss. 
c. Servings are adjusted based on caloric intake. 
 







 The main independent variable of interest was intervention status.  From the 
intervention status, change in fitness was isolated from the dietary component of the 
intervention in a logistical regression.  The two intervention groups, one with a dietary 
component and one without, were combined because the physical activity and weight loss 
goals were the same.   Although there was a dietary component to the intervention, it was 
held constant in a logistical regression analysis.   See statistical analysis section for 
details.  Physical activity was used as a means to increase aerobic fitness in this study.  
However, the change in fitness was chosen as the only independent variable because 
there were intervention related changes in fitness but not for physical activity.  The 
investigators believe that this was due to sub-optimal measures for physical activity in 
this population (Writing Group of PREMIER, 2003). 
 The main outcome, or dependent variable, is the presence of the Metabolic 
Syndrome as defined by the NCEP at the 6 month and/or the 18 month follow up.  
Metabolic Syndrome is defined by the NCEP as having three or more of the following 
criteria: central obesity, hypertriglyceridaemia, low HDL-C, hypertension, or an elevated 
fasting glucose (Zimmet et al, 2005).  For a complete list of the specifications, refer to 
Table 1.  Six months was chosen as the initial follow up because some of the participants 
had been diagnosed with stage 1 hypertension at baseline.  After 6 months, it is 
recommended that individuals with persistent blood pressure of 140/90 or higher be 







 Aerobic fitness was assessed using a sub-maximal treadmill exercise test 
developed specifically for the PREMIER trial (Writing Group of PREMIER, 2003).  The 
test was designed to achieve an age and sex specific moderate intensity (approximately 
60% of maximal METS).  The protocol lasted a total of ten minutes (Writing Group of 
PREMIER, 2003) with two, three minute stages along with warm up and cool down 
stages (Young et al, 2005).  The first stage achieved a light intensity effort, 
(approximately 40% of maximal METs), and the second stage achieved a moderate 
intensity effort, (approximately 60% of estimated METs) (Writing Group of PREMIER, 
2003).  Heart rate was taken at the end of each minute.  The test was over when either the 
participant reached 85% of his/her age-predicted maximal heart rate (220-age), or when 
the protocol was completed (Young et al, 2005).  The main outcome was heart rate at the 
end of stage two, or the last available stage for participants who stopped early because of 
heart rate (Writing Group of PREMIER, 2003).  For this paper, the primary outcome is a 
change in aerobic fitness as defined by a change in stage 2 heart rate.  The baseline stage 
2 heart rate was subtracted from the stage 2 heart rate at each respective follow-up visit to 
get a change in heart rate (or fitness) variable.  Heart rate was chosen because it has been 
shown to have a relatively linear relationship to VO2.  The correlation between heart rate 
and VO2 is >0.90 (ACSM, 2006).  Therefore, the change in stage 2 heart rate was used as 
a continuous variable to establish a change in fitness.  A lower heart rate at the end of 
stage two implies an improvement in fitness.  Participants without a baseline or follow-up 
fitness test will be excluded from the main analysis. 
 Blood Pressure measurements were taken by trained individuals with a random 




Labarthe et al (1973), the Random Zero sphygmomanometer means for both systolic and 
diastolic blood pressure did not significantly differ from the respective blood pressure 
means of 6 other blood pressure instruments, showing concurrent validity (Labarthe, 
Hawkins, and Remington, 1973).  This instrument is often referred to as the “gold 
standard” of blood pressure measurements in epidemiological studies because it 
attenuates the zero digit preference (Gillman and Cook, 1995).  Blood pressure 
measurements were obtained after the participant sat quietly for at least 5 minutes.  Two 
measurements were taken at each visit (baseline, 3 months, 6 months, and 18 months), all 
on the right arm with an appropriate sized cuff.  There was at least a 30 second interval 
between each measurement.  Four sets of blood pressure measurements were taken over 
three months and averaged to determine baseline blood pressure.  The same protocol was 
used for the 6 and 18 month follow-ups (Young et al, 2005).   
 Triglycerides and HDL cholesterol were measured from a blood sample obtained 
after a 12 hour fast (Writing Group of PREMIER, 2003).   Analyses were performed at 
the Core Laboratory for Clinical Studies at Washington University, St. Louis, MO 
(Svetkey et al, 2003). 
 Serum glucose levels were assessed using the intravenous glucose tolerance test 
with minimal model analysis after a 12 hour fast (Ard, Grambow, Liu, Slentz, Kraus, and 
Svetkey, 2004).  Serum glucose levels were measured on the Roche Cobas Mira Plus 
using the Hexokinase/G-6-PD methodology (Ard et al, 2004).  When this assay was 
compared to two others, the “r” correlations were greater than 0.95, showing concurrent 




 Waist circumference was measured by trained staff using anthropometric 
measuring tape at baseline, 6 months, and 18 months (Ard et al, 2004).  Waist 
circumference has been found to be better correlated with cardiovascular disease risk 
factors such as glucose, high blood pressure, and a negative lipid profile than body mass 
index (BMI) (Zhu, Wang, Heshka, Heo, Faith, and Heymsfield, 2002).  Waist 
circumference is also highly correlated to BMI at 0.891 and 0.880 in men and women, 
respectively (Zhu et al, 2002).  When the intraclass reliability of waist circumference was 
measured in 4 slightly different sites on the waist in both men and women, the reliability 
coefficients of all sites were above 0.99 (Wang, Thornton, Bari, Williamson, Gallagher, 
Heymsfield, Horlick, Kotler, Laferrère, Mayer, Pi-Sunyer, and Pierson, 2003). 
 All measurements were taken at baseline, six months, and 18 months.  Six months 
was chosen as the primary follow up point for three reasons: (1) those with stage one 
hypertension need to begin medication after 6 months; (2) 6 months gives maximum 
blood pressure data for analysis; and (3) adherence to lifestyle changes peaks at 6 months 
(Svetkey et al, 2003).  Although 6 months was the primary outcome, it was the 18 month 
follow up data that gives the PREMIER study its public health importance.  Previous 
studies have shown that health benefits persist up to 6 months, but it is important to see if 
it is possible for these benefits to persist over time (Svetkey et al, 2003). 
Statistical Analysis 
  
Participants were classified as having the Metabolic Syndrome according the 
NCEP definition.  Briefly, they had to have three or more of the following, above normal 




fasting glucose.  Refer to table 1 for the specific criteria for this classification.  At 
baseline, there were no significant differences among the participants in any of the three 
intervention groups (Writing Group of PREMIER, 2003).   See table 3 for complete 
baseline characteristics.  For participants with missing data the following adjustments 
will be applied: if only 1 criterion was missing, but the participant still had 3 or more of 
the risk factors associated with the syndrome, that participant was classified as having the 
Metabolic Syndrome.  However, if one or more criterion was missing and the participant 
did not have three or more of the risk factors, that participant was eliminated from the 
analysis (Lien et al, 2007).   
For the purpose of this paper, the two intervention treatment groups were 
combined into one to isolate the effects of the change in fitness on the Metabolic 
Syndrome relative to the advice-only control group.  To test for that effect, a logistic 
regression analysis model was used.  The main independent variable was intervention 
status.  To isolate the change in fitness from other aspects of the intervention, the dietary 
component of the intervention was adjusted for in the model along with other possible 
confounding factors such as race, gender, age, trial site, and cohort.  The specific dietary 
components that were adjusted for are as follows: total calories per day, sodium intake 
per day, alcohol consumption per day, percentage of kilocalories from fat and saturated 
fat per day, the fruit and vegetable servings, and the low fat dairy servings.  For the 
above-stated variables, the average respective follow-up values were co-varied for in the 
model.  Analyses were run with and without weight status to determine if possible effects 
of fitness change on Metabolic Syndrome are independent of or mediated by change in 




be done by race to further test for the effect of race on Metabolic Syndrome prevalence in 
response to treatment status.  For all analyses, a P value of 0.05 will be needed to reach 
significance. 
Results 
Baseline Characteristics  
Of the 810 participants randomized, 6 did not have sufficient data to be classified 
as having or not having Metabolic Syndrome and were excluded.  Therefore, 804 
participants were included in the present analysis.  The 804 participants analyzed for the 
current analysis were divided into two treatment groups, advice-only (control) group 
(n=271) and a combined treatment group (n=533).  The latter group consisted of the 
established guidelines group and the established guidelines plus DASH diet group from 
the original PREMIER study design.  See figure 1 for details.   
Table 7 displays baseline characteristics of the 804 included participants by their 
respective randomized treatment groups.  The mean age in both groups was 
approximately 50 years.  In the advice-only group, 63.5% were female and 36.9% were 
African American.  In the combined lifestyle treatment group, 61.5% were female and 
33.0% were African American.  Most participants had at least some college education, 
did not currently smoke cigarettes, and were overweight or obese.   The average stage 2 
heart rate was approximately 130 beats per minute (bpm) in both groups.  Approximately 
half of the participants in each group had Metabolic Syndrome at baseline.  The 
prevalence was 47.2% and 49.9% in the advice-only and combined treatment groups, 
respectively.  The prevalence of Metabolic Syndrome in African Americans (42.8%) was 




Table 7.  Baseline Characteristics by Randomized Treatment Group                                                    
 
                                                                  Advice Only   Combined Treatment Groups*                   
Characteristic                                              (n = 271)                    (n = 533) 
Age, mean (SD) y                                        49.5 (8.9)                   50.2 (8.9) 
Female                                                          63.5%                          61.5%  
Race or ethnicity                         
   African American       36.9%   33.0% 
   Non-African American                          63.1%                          70.0% 
Annual Household Income 
     <$30,000                                                 14.0%                          8.4% 
     $30,000 - $60,000                                   30.3%                       32.3% 
     >$60,000                                                 51.7%                      55.9% 
     Unknown (no answer)                             4.1%                            3.4% 
Education  
     High school or less                                  10.7%                          8.4% 
     Some college                                          60.5%                         58.2% 
     Some graduate school                              28.8%                          33.4% 
Current Cigarette Smokers                           5%                              5% 
BMI, mean (SD)                                        32.9 (5.58)                  33.2 (5.9) 
Weight Classification 
     Non-overweight (BMI < 25)                   4.8%                        4.5% 
     Overweight (BMI 25-29.9)                     27.7%                         29.8% 
     Obese (BMI >30)                                    66.8%                      64.7% 
Stage 2 Heart Rate, mean bpm**  130.2 (14.5)  130.1 (14.4)   
Current Metabolic Syndrome                       47.2%                         49.9% 
Metabolic Syndrome Risk Factors*** 
     Central waist obesity                               79.3%                        80.5% 
     Hypertriglyceridaemia                             31.7%                          34.3% 
     Low HDL-C                                            43.5%                        49.0% 
     Elevated blood pressure                              74.5%                         77.9% 
     Fasting glucose > 109 mg/dl                   9.6%                       14.1% 
*Combination of the Established Guidelines group and the Established Guidelines plus DASH diet group 
form original PREMIER study  
**The mean stage 2 heart rate, measured in beats per minute (bpm), as determined from the VO2 max 
treadmill test to determine fitness level.  
***Metabolic Syndrome as classified by NCEP guidelines  
• Central waist obesity (F): >88cm; (M): >102cm 
• Hypertriglyceridaemia: triglycerides > 149 mg/dl 
• HDL-C: (F): < 50 mg/dl; (M): < 40 mg/dl  
• Elevated blood pressure: blood pressure > 129/84 OR medication 







Relationship of Treatment, Fitness and Metabolic Syndrome 
 At the six month follow-up, treatment group assignment (advice-only control 
versus the combined lifestyle intervention groups) was significantly related to an increase 
in aerobic fitness (F=0.008).  However, this relationship was no longer significant at the 
18 month follow-up (F=0.85).  Figure 2 shows the unadjusted percentages of participants, 
by treatment group assignment, with Metabolic Syndrome at baseline, 6 month follow-
up, and 18 month follow-up.  At baseline and both the 6 and 18 month follow-up visits, 
fitness was significantly related to the presence of Metabolic Syndrome.  Lower fitness 
levels was associated with higher prevalence of Metabolic Syndrome (P<0.02; P<0.0001; 
and P<0.0001 for each time point, respectively).  This significant relationship remains 
after adjusting for age, sex, BMI, race, and baseline fitness levels (P<0.004; P<0.0001; 
and P<0.0001 for each time point, respectively).  Figure 3 shows the change in stage 2 
heart rate, representing aerobic fitness, of the participants by Metabolic Syndrome Status 
at each respective time point.  From baseline to 6 months as well as from baseline to 18 
months, the fitness level of participants in both randomized treatment groups increased.  
Importantly, fitness level increased at 6 months and 18 months, regardless of race, 
although African Americans had a slightly more modest increase than non-African 
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Figure 3 


























Primary Outcome: Predictors of Metabolic Syndrome at 6 and 18 month follow-ups 
 The main results for the change in aerobic fitness and prevalence of Metabolic 
Syndrome at 6 months are presented in Table 8.  All data examining the change in 
aerobic fitness has only 665 participants at the 6 month follow up and 656 participants at 
the 18 month follow up due to missing fitness data.  The assigned treatment group had no 
effect on prevalence of Metabolic Syndrome at the 6 month follow-up (P=0.17).  
However, all participants increased their fitness, by lowering their stage 2 heart rate, 
regardless of treatment status (Figure 4).  Importantly, a positive change in aerobic fitness 
significantly impacted the odds of having Metabolic Syndrome at the 6 month follow-up 
(P=0.0003).  At six months, a one beat per minute reduction in stage 2 heart rate was 
associated with a 4% reduction in the odds of prevalent metabolic syndrome (OR: 0.96, 
CI: 0.94 – 0.98).   
 The 18 month results are presented in table 9.  At 18 months, the assigned 
treatment group still had no significant effects.  Importantly, the decreased odds for the 
prevalence of Metabolic Syndrome due to an increase in aerobic fitness remained the 
same at 18 months as it was for the 6 month follow-up (OR: 0.96; CI: 0.94 – 0.98).  The 
odds for having Metabolic Syndrome were still 4% less for every one beat per minute 
reduction in stage 2 heart rate (P<0.0005).  Interestingly, race had no significant effect on 













Table 8. Change in Aerobic Fitness and Prevalence of Metabolic Syndrome at 6 
Months* 
    Odds Ratio P value  95%Confidence Interval_ 
Treatment **   0.71  0.17  0.44 – 1.15 
1 beat change in HR  0.96  .0003  0.94 – 0.98 
Race (non-AA vs. AA)  0.71  0.21  0.41 – 1.21 
*Models for treatment and change in fitness variables were separate.  Both controlled for site, cohort, age, 
sex, race, BMI, baseline fitness, baseline Metabolic Syndrome, and dietary variables (daily alcohol intake, 
dairy consumption, fruit and vegetable intake, total fat intake, sodium consumption, and fat servings per 
day)  







Table 9. Change in Aerobic Fitness and Prevalence of Metabolic Syndrome at 18 
months* 
    Odds Ratio P value  95%Confidence Interval____ 
Treatment***   1.00  1.00  0.63 – 1.58 
1 beat change in HR  0.96  0.0005  0.94 – 0.98  
Race (non-AA vs. AA)  0.70  0.19  0.41 – 1.19 
*Models for treatment and change in fitness variables were separate.  Both adjusted for site, cohort, age, 
sex, race, BMI, baseline fitness, baseline Metabolic Syndrome, and dietary variables (daily alcohol intake, 
dairy consumption, fruit and vegetable intake, total fat intake, sodium consumption, and fat servings per 
day) 

































Baseline 6 Month 18 Month  
Predictors of Metabolic Syndrome at 6 months stratified by presence of Metabolic 
Syndrome at baseline 
 Presence of Metabolic Syndrome at baseline was a significant predictor of having 
Metabolic Syndrome at the 6 month follow-up.  Therefore, we stratified the analysis by 
presence of Metabolic Syndrome at baseline.  Race was not reported for this analysis 
because it was not a significant predictor of Metabolic Syndrome prevalence at 6 months.  
Table 10 displays the results for those with and without Metabolic Syndrome at baseline. 
Of the 323 participants who had Metabolic Syndrome at baseline, only 184 still had it at 
6 months.  Of the 338 participants who were free of Metabolic Syndrome at baseline 26 
participants had it at six months.  Only 11 of these participants were in the advice-only 




 The treatment status had no effect on participants with or without Metabolic Syndrome 
at baseline.  For individuals with baseline Metabolic Syndrome, the odds of no longer 
having Metabolic Syndrome at the 6 month follow-up are significantly increased with 
increasing aerobic fitness (P<0.0001).  For every one beat per minute reduction in stage 2 
heart rate the odds of still having it at baseline are decreased by 5% (OR:0.95, CI: 0.92 – 
0.97).  However, for those who did not have Metabolic Syndrome at baseline, a change in 
aerobic fitness had no significant impact on the incidence of Metabolic Syndrome at the 6 
month follow-up.   
Table 10. Change in Aerobic Fitness on Prevalence of Metabolic Syndrome at 6 
months stratified by baseline Metabolic Syndrome status* 
 
   N Odds Ratio P value 95% Confidence Interval 
Treatment** 
     Baseline MS 
Yes  323 0.65  0.14  0.36 – 1.15 
No   338 0.70  0.46  0.27 – 1.81 
Change in Aerobic Fitness 
     Baseline MS 
Yes  317 0.95  <0.0001 0.92 – 0.97 
No   338 1.00  0.81  0.95 – 1.04    
 
*Models for treatment and change in fitness variables were separate.  Both controlled for site, cohort, age, 
sex, race, BMI, baseline fitness, baseline Metabolic Syndrome, and dietary variables (daily alcohol intake, 
dairy consumption, fruit and vegetable intake, total fat intake, sodium consumption, and fat servings per 
day)  
**Advice-only versus combined treatment group 
 
Predictors of Metabolic Syndrome at 18 months stratified by presence of Metabolic 
Syndrome at Baseline 
 Table 11 displays the results for the participants with and without Metabolic 
Syndrome at the 18 month follow-up.  Treatment group was not a significant predictor of 
follow-up Metabolic Syndrome for participants with or without Metabolic Syndrome at 




fitness by one beat per minute reduced the odds for having Metabolic Syndrome at 18 
months by 6% (OR: 0.94, CI: 0.92 -0.97).  Of the 323 participants who had Metabolic 
Syndrome at baseline, only 116 still had it at the 18 month follow-up.  Of the 338 
participants who were Metabolic Syndrome-free at baseline, 11 participants from the 
advice-only control group and 22 participants from the combined lifestyle group got 
Metabolic Syndrome at 18 months.  For participants who did not have Metabolic 
Syndrome at baseline, an increase in fitness is not a significant predictor of Metabolic 
Syndrome at 18 months. 
Table 11.  Change in Aerobic Fitness on Prevalence of Metabolic Syndrome at 18 
months stratified by baseline Metabolic Syndrome status* 
 
   N Odds Ratio P value 95% Confidence Interval 
Treatment** 
     Baseline MS 
Yes   0.95  .86  0.55 – 1.64 
No    1.03  .96  0.39 – 2.69 
Change in Aerobic Fitness   
     Baseline MS 
Yes   0.94  <.0001  0.92 – 0.97 
No    0.99  .62  0.95 – 1.03    
*Models for treatment and change in fitness variables were separate.  Both controlled for site, cohort, age, 
sex, race, BMI, baseline fitness, baseline Metabolic Syndrome, and dietary variables (daily alcohol intake, 
dairy consumption, fruit and vegetable intake, total fat intake, sodium consumption, and fat servings per 
day)  
** Advice-only versus combined treatment group 
 
Predictors of Metabolic Syndrome at 6 months stratified by weight loss 
Baseline BMI was a significant predictor of prevalence of Metabolic Syndrome at 
the 6 month and 18 month follow-up (OR: 0.92, CI: 0.88 – 0.96; and OR: 0.91, 0.87 – 
0.95, respectively).  Therefore, we ran a second stratified analysis by weight loss.  
Because race was not a significant predictor of Metabolic Syndrome prevalence at either 
follow-up, results for race are not shown in this analysis.  Further, there was not a 




(P=0.45 and P=0.88, respectively) (results not shown).  Participants were divided into 2 
groups; the first were those who lost at least 4kg of body weight (n=397) and the second 
were those who lost less than 4kg of body weight (n=248).  For those who lost at least 
4kg, the average weight loss was 10.0kg (+/-15.2kg) at 6 months.  (Figure 5)  The results 
for this analysis are presented in table 12.  Treatment group assignment had no significant 
effect on either weight group.  An increase in aerobic fitness was only a significant 
predictor of Metabolic Syndrome for the participants who lost greater than 4 kg of body 
weight (OR: 0.97; CI: 0.94 - 0.99).  For each beat per minute reduction in stage 2 heart 
rate, the odds of having Metabolic Syndrome at the 6 month follow-up were 3% less 
(P=0.01).  For those who did not lose at least 4kg of body weight, an increase in aerobic 
fitness was not a significant predictor of Metabolic Syndrome at the 6 month follow-up 
(P=0.59). 
Figure 5 
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Table 12. Change in Aerobic Fitness on Prevalence of Metabolic Syndrome at 6 
months stratified by weight loss status* 
   N Odds Ratio P value 95% Confidence Interval 
Treatment** 
     Weight Group 
Lost >4 kg 397 0.74  0.45  0.34 – 1.61 
Lost <3.99 kg 248 1.83  0.13  0.84 – 3.97 
1 beat change in stage 2 HR   
     Weight Group   
Lost >4 kg 397 0.97  0.01  0.94 – 0.99 
Lost <3.99 kg 248 0.99  0.59  0.94 – 1.03 
*Models for treatment and change in aerobic fitness are separate.  Both are adjusted for site, cohort, age, 
sex, race, baseline body weight, baseline fitness, baseline Metabolic Syndrome, and dietary variables (daily 
alcohol intake, dairy consumption, fruit and vegetable intake, total fat intake, sodium consumption, and fat 
servings per day) 
**Advice-only versus combined treatment group  
 
Predictors of Metabolic Syndrome at 18 months stratified by weight loss 
 As previously mentioned, BMI was a significant predictor of the prevalence of 
Metabolic Syndrome at 18 months (OR: 0.91, 0.87 – 0.95).  Table 13 displays the 18 
month follow-up results of Metabolic Syndrome stratified by weight group.  Treatment 
group remained insignificant for the 18 month prevalence of Metabolic Syndrome.  For 
the participants who lost at least 4 kg of body weight, an increase in aerobic fitness was a 
significant predictor of Metabolic Syndrome at 18 months (OR: 0.97; CI: 0.94 -1.00).  
For participants in the weight loss group, the odds of having Metabolic Syndrome at the 
18 month follow-up are decreased by 3% for every one beat per minute reduction in stage 
2 heart rate (P=0.03).  For those who did not lose at least 4kg of body weight at 18 
months, an increase in fitness was not a significant predictor of Metabolic Syndrome for 
that time frame.  However, there was a trend toward significance (P=0.07), showing that 
an increase in aerobic fitness may be a more significant predictor of Metabolic Syndrome 






Table 13. Change in Aerobic Fitness on Prevalence of Metabolic Syndrome at 18 
months stratified by weight loss status * 
   N Odds Ratio* P value 95% Confidence Interval 
Treatment** 
     Weight Group 
Lost >4 kg  1.33  .44  0.65 – 2.73 
Lost <3.99 kg  1.41  .34  0.70 – 2.85 
1 beat change in stage 2 HR   
     Weight Group   
Lost >4 kg  0.97  .03  0.94 – 1.00 
Lost <3.99 kg  0.96  .07  0.93 – 1.00 
 
*Models for treatment and change in aerobic fitness are separate.  Both are adjusted for site, cohort, age, 
sex, race, baseline body weight, baseline fitness, baseline Metabolic Syndrome, and dietary variables (daily 
alcohol intake, dairy consumption, fruit and vegetable intake, total fat intake, sodium consumption, and fat 
servings per day) 
**Advice-only control versus treatment group 
 
Secondary Outcome: Predictors of individual risk factors for Metabolic Syndrome at 6 
months 
 The combined lifestyle treatment group had no significant effects on the 
prevalence of Metabolic Syndrome at either follow-up.  However, we ran a series of 
models predicting each respective risk factor in order to determine if any individual risk 
factors of the Metabolic Syndrome were being impacted by the combined lifestyle 
treatment group.  Because aerobic fitness was a significant indicator of follow-up 
Metabolic Syndrome, we were interested in precisely which risk factors it had the largest 
impact on.  Table 14 displays the predictors for these individual risk factors at the 6 
month follow-up.  Of the five risk factors included in the Metabolic Syndrome definition 
(elevated blood pressure, elevated triglycerides, high waist circumference, low HDL and 
high fasting glucose), treatment group was a significant predictor of elevated blood 
pressure (OR: 0.54; CI: 0.36 – 0.82) and high waist circumference (OR: 0.42 CI: 0.19 – 
0.95), but not for any of the other Metabolic Syndrome risk factors.  Participants in the 





(P<0.002) or a high waist circumference (P<0.02), respectively, at 6 months compared to 
the advice-only control.  An increase in aerobic fitness had a larger impact on the 
individual risk factors or Metabolic Syndrome.  All risk factors except for low HDL are 
significantly impacted by an increase in aerobic fitness.  For elevated blood pressure and 
elevated triglycerides, the odds of having Metabolic Syndrome at 6 months are 2% and 
3% less, respectively, with each beat per minute decrease in stage 2 heart rate (OR: 0.98; 
CI: 0.96 – 1.00; and OR: 0.97; CI: 0.94 – 0.99).  For both high waist circumference and 
high fasting glucose, the odds of having Metabolic Syndrome at 6 months are 7% less for 
each beat per minute decrease in stage 2 heart rate (OR: 0.93; CI: 0.90 – 0.97; OR: 0.93; 
CI: 0.90 – 0.97).   
Secondary Outcome: Predictors of individual risk factors for Metabolic Syndrome at 18 
months 
 Table 15 displays the predictors for the individual Metabolic Syndrome risk 
factors at 18 months.   The treatment group remained a significant predictor of high waist 
circumference (OR: 0.34; CI: 0.16 – 0.70) but not elevated blood pressure at 18 months.  
Participants in the combined lifestyle treatment group were 66% less likely to experience 
high waist circumference measurements than those in the advice-only control group 
(P=0.003).  An increase in aerobic fitness remained a significant predictor of elevated 
blood pressure, high waist circumference, and high fasting glucose (OR: 0.97; CI: 0.95 – 
0.99; OR: 0.95; CI: 0.92 – 0.98; OR: 0.95; CI: 0.92-0.99).  An increase in aerobic fitness 




Table 14. Change in Aerobic Fitness and Prevalence of Individual Risk Factors for Metabolic Syndrome at 6 Months* 
 
    Treatment    1 beat change in HR      
    OR** CI (95%) P  OR CI(95%) P   
  
Elevated Blood Pressure 0.52 0.34 – 0.79 .002  0.98 0.96 – 1.00 .02     
Elevated Triglycerides 0.76 0.46 – 1.26 .29  0.97 0.94 – 0.99 .005     
High Waist Circumference 0.39 0.18 – 0.87 .02  0.93 0.90 – 0.97 .0001     
Low HDL   1.23 0.74 – 2.06 .43  1.01 0.99 – 1.03 .45     
High Fasting Glucose  0.68 0.33 – 1.40 .30  0.93 0.90 – 0.97 .0003    
 
* Separate models were adopted for the treatment and change in fitness variables.  Both adjusted for site, cohort, age, sex, race, BMI, baseline fitness, 
baseline status of each respective risk factor, and dietary variables (daily alcohol intake, dairy consumption, fruit and vegetable intake, total fat intake, 
sodium consumption, and fat servings per day) 
**Advice-only versus combined treatment group  
Referent is absence of risk factor 
 
Table 15. Change in Aerobic Fitness and Prevalence of Individual Risk Factors for Metabolic Syndrome at 18 Months* 
 
    Treatment    1 beat change in HR      
  
    OR** CI(95%) P  OR CI(95%) P   
  
Elevated Blood Pressure 0.93 0.62 – 1.36 .67  0.97 0.95 – 0.99 .0008     
Elevated Triglycerides 0.68 0.40 – 1.16 .16  0.99 0.96 – 1.01 .34     
High Waist Circumference 0.34 0.16 – 0.70 .003  0.95 0.92 – 0.98 .003     
Low HDL   0.94 0.60 – 1.49 .80  0.99 0.97 – 1.01 .25     
High Fasting Glucose  1.12 0.55 – 2.31 .76  0.95 0.92 – 0.99 .009     
*Separate models were adopted for the treatment and change in fitness variables.  Both adjusted for site, cohort, age, sex, race, BMI, baseline fitness, 
baseline status of each respective risk factor, and dietary variables (daily alcohol intake, dairy consumption, fruit and vegetable intake, total fat intake, 
sodium consumption, and fat servings per day) 
**advice-only versus combined treatment group  






In our study population, the prevalence of Metabolic Syndrome at baseline was 
approximately 50%.  Although this is much higher than the 35% prevalence of Metabolic 
Syndrome in the overall population as reported by the most recent NHANES data, our 
sample consisted of only individuals with above optimal blood pressure.  Ford (2005) 
reported that individuals with hypertension have greater than a 2 fold increase in risk for 
having the Metabolic Syndrome when compared to individuals with normal blood 
pressure (Ford, 2005).  Therefore, it was to be expected that the prevalence of Metabolic 
Syndrome in the current sample would be higher than the national average.   
The prevalence of Metabolic Syndrome decreased from baseline to 6 months by 
12% and from baseline to 18 months by 16% in the advice-only control group.  In the 
treatment group, the prevalence of Metabolic Syndrome decreased by 18% and 17% at 6 
and 18 months, respectively.  These prevalence decreases appear reasonable as they 
compare with prevalence decreases reported by Stewart and colleagues (2005) in the 
analysis of the Senior Hypertension and Physical Exercise trial.  Stewart et al reported 
that in men and women aged 55-75 years, after a 6 month exercise trial, the prevalence of 
Metabolic Syndrome decreased by 17.7% in the exercise group and 8.2% in the control 
group (Stewart et al, 2005).  Although in the present analysis the control group and the 
treatment group showed similar decreases, this can be explained because the control 
group also changed their fitness and lost weight.    
We hypothesized that the treatment status would cause an increase in aerobic 




have significantly less prevalence of Metabolic Syndrome at both follow-up time points.  
Our results did not fully support this hypothesis.  Treatment status had no significant 
effects on Metabolic Syndrome prevalence at either the 6 or 18 month follow-up.  
However, an increase in aerobic fitness was significantly related to treatment status 
(P=0.008) at 6 months only.  At 18 months, the fitness levels between the two 
intervention groups were not significantly different, which could explain the loss of 
significance between aerobic fitness and treatment status.  At both 6 and 18 months, 
aerobic fitness was a significant predictor of Metabolic Syndrome prevalence 
independent of treatment status.  Therefore, aerobic fitness is a mediator between 
treatment status and follow-up prevalence of Metabolic Syndrome at 6 months.   
At 18 months increasing aerobic fitness no longer explains the lack of 
significance for treatment status.  In addition to the similarities between the fitness levels 
of participants in both intervention groups, it is plausible that other mediators, such as 
weight loss, were contributing to the decreased Metabolic Syndrome status.  When the 
main results for PREMIER were published, it was reported that participants in the control 
group from this study lost weight (Writing Group of PREMIER, 2003).  We found that 
weight loss was a significant contributor to decreased Metabolic Syndrome prevalence at 
6 and 18 months.  Thus, it is plausible that weight loss was the mediator between 
treatment status and Metabolic Syndrome prevalence at 18 months. 
There was an inverse relationship between increasing aerobic fitness and 
prevalence of Metabolic Syndrome in our sample.  This relationship was to be expected 
as it agrees with previous cross sectional (Kullo et al, 2002; Farrell, et al, 2004; Lee, Kuk 




Palaniappan et al, 2004; Ekelund et al, 2005).  Two studies of adults (Mathieu, Brochu, 
and Beliveau, 2008; & Carnethon et al, 2003) show support for our results.  Mathieu et al 
(2008) found that increasing aerobic capacity had a 0.28 effect size in decreasing the 
prevalence of Metabolic Syndrome by 25%.  However, that study included only 29 
participants.  Our results have greater public health impact due to our large and racially 
diverse sample.  In the CARDIA study, a sub-set of participants with an average age of 
25 at baseline, took a treadmill duration fitness test at baseline and at a 7 year follow-up.  
After adjusting for covariables, improving aerobic fitness was associated with 
approximately a 50% reduction in for developing Metabolic Syndrome after 7 years, 
showing a protective benefit of cardiovascular fitness.  However, there is no evidence 
from this study of fitness being used as a treatment for the Metabolic Syndrome.  In 
contrast, Thompson et al found that in Native American women, aerobic fitness was not 
significantly associated with Metabolic Syndrome after adjusting for age and BMI.  
However, the sample was not racially diverse and included only women.  The mean age 
was also 20 years younger than the age of participants in our sample.  Therefore, it 
appears that higher aerobic fitness levels have a protective effect against prevalence of 
Metabolic Syndrome in middle-aged adults. 
Further analysis revealed that for the participants who had Metabolic Syndrome at 
baseline, the prevalence of Metabolic Syndrome at 6 and 18 months decreased by 
approximately 36% and 49%, respectively, in response to an increase in aerobic fitness.  
These results are consistent with other studies showing that Metabolic Syndrome is 
reversible by improving aerobic fitness (Anderssen, Carroll, Urdal, and Holme, 2006; 




(2006) found that for every one mL/kg/min unit increase in aerobic fitness, there is a 32% 
increase in the likelihood that Metabolic Syndrome (using the IDF definition) will be 
reversed after one year.  Although it was a randomized controlled trial, only 188 men 
were included in the analyses.  Maxwell et al (2008) found that after a three-year period, 
all participants who reversed their Metabolic Syndrome also improved their aerobic 
fitness.  Participants who were Metabolic Syndrome-free at baseline, but had Metabolic 
Syndrome after 3 years, decreased their fitness.  However, the magnitude of the impact of 
aerobic fitness on Metabolic Syndrome was not reported.  Although both aerobic fitness 
and Metabolic Syndrome changes were statistically tested, the relationship between them 
was not.  It is interesting to note that the reversal of Metabolic Syndrome due to increased 
aerobic fitness stays stable or improves over time.  Changing aerobic fitness may be one 
important aspect of improving long-term health effects.   
It was hypothesized that race would be a significant predictor of follow-up 
prevalence of Metabolic Syndrome.  It was expected that the African American subgroup 
would see a lesser change than the non-African American participants.  However, race 
was not a significant indicator of Metabolic Syndrome at either follow-up.  It has been 
previously reported that there are physiological and cultural differences between African 
Americans and non-African Americans that make African Americans more prone to 
certain cardiovascular risk factors, specifically, hypertension (Thomas et al, 1987 & 
Reiner et al, 2007).  In a review article, Jamerson (1993) reported that African Americans 
also respond differently to treatment than non-African Americans (Jamerson, 1993).  
However, in the current study, all participants lost weight and improved their fitness, 




that improving fitness and losing weight should be the primary treatment targets for 
Metabolic Syndrome in African Americans and non-African Americans.  For 
interventions aiming to reduce the prevalence of Metabolic Syndrome through an 
improvement in aerobic fitness, it does not appear to be necessary to provide separate 
interventions for these two races. 
In our sample, BMI was one of the predictors of Metabolic Syndrome at both 6 
(OR: 0.92, CI: 0.88 – 0.96) and 18 (OR: 0.91, 0.87 – 0.95) months.  This relationship has 
been shown in many previous studies examining predictors of Metabolic Syndrome 
(Mathieu et al, 2008; Okura et al, 2007, Thompson, Herman, Helitzer, Wilson, Whyte,, 
Perez, & Wolfe, 2007; Ribisl, Lang, Jaramillo, jakicic, Stewart, Bahnson, Bright, Curtis, 
Crow, & Soberman, 2007; Eisenmann, Wlek, Wickel, & Blair, 2006; and Carnethon et al, 
2004).  Although our primary analysis indicated that aerobic fitness was significantly 
related to prevalence of Metabolic Syndrome even after adjusting for BMI, the 4 kg 
weight loss stratification results suggests that body weight is an important mediator 
between aerobic fitness and prevalence of Metabolic Syndrome at 6 and 18 months.  
Importantly, our results are consistent with previous research showing the link between 
weight loss and cardiovascular disease risk factors associated with Metabolic Syndrome.  
Carnethon et al (2004) found that for every 4.5kg of body weight gained, risk for 
Metabolic Syndrome increases 23%.  Krebs et al reported that that a sustained loss of 
10% body weight is needed for long term health benefits (Krebs, Evans, Conney, Mishra, 
Fruhbeck, Finer, & Jebb, 2002). 
It is apparent from our results that in a racially diverse sample of middle aged 




Syndrome after 6 and 18 months.  However, this increase in fitness is more strongly 
associated with certain risk factors that constitute Metabolic Syndrome than it is with 
others.  Of the five risk factors included in the Metabolic Syndrome definition (elevated 
blood pressure, elevated triglycerides, high waist circumference, low HDL and high 
fasting glucose), all except for low HDL are significantly impacted by an increase in 
aerobic fitness after 6 months.  These results are in agreement with Mathieu et al (2008), 
who reported that a physical activity and aerobic fitness intervention significantly 
improved blood pressure, waist circumference, and HDL cholesterol.  Although there 
were some discrepancies in the risk factors, they can be explained by the many 
differences in the two study designs.  In the Mathieu study, the effects of increased 
aerobic fitness were not separated from the effects of the physical activity for the 
individual risk factor analyses.  This study also had fewer participants (n=29) and more 
normal weight than overweight participants (15:14) (Mathieu et al, 2008).  The strong 
differences in the sample population between our study and this one could explain the 
slight differences in the results. 
At the 18-month follow-up, triglycerides were no longer significantly impacted by 
an increase in aerobic fitness, and HDL cholesterol still showed no significant changes 
due to aerobic fitness increases.  These results do not compare to the changes reported by 
Maxwell et al (2008) after a retrospective analysis on Metabolic Syndrome risk factor 
changes with fitness level changes.  Maxwell and colleagues found that all of the 
Metabolic Syndrome risk factors measured were positively reduced due to an increase in 
fitness level after 3 years.  Waist circumference was the only risk factor not measured in 




and Metabolic Syndrome risk factors was not statistically tested.  It is only known that 
fitness increased and the risk factors decreased.  Similarly, Hightower et al (2007) 
reported that after 2 years, participants of a health and fitness assessment center study 
reduced all risk factors of the Metabolic Syndrome except for waist circumference (not 
calculated).  Interestingly, in this study, the most dramatic difference between 
participants who reversed their Metabolic Syndrome and those who did not was the 
triglyceride level and HDL cholesterol (Hightower et al, 2007).  The previously 
mentioned results are in direct contrast with the results found in the current analysis, as 
we found that after 18 months, triglyceride level and HDL cholesterol were no longer 
impacted by an increase in aerobic fitness.  However, in the Hightower study, fitness 
changes were not reported and all results were due to the combined aspects of the 
intervention.  It is plausible that one of the other aspects of the health and fitness 
intervention was responsible for the large changes in triglycerides and HDL cholesterol.  
Overall, our results show that all risk factors of the Metabolic Syndrome except for 
triglycerides and HDL cholesterol can improve and be maintained long-term by 
increasing aerobic fitness.  However, due to previously published results, it is possible 
that aerobic fitness may have an impact on all five risk factors and is an important 
intervention tool to decrease Metabolic Syndrome and all of the risk factors it entails. 
Our study is not without limitations.  As previously mentioned, there may not 
have been sufficient distinction between the control group and the treatment group.  All 
participants in the trial were highly motivated individuals who were willing to participate 
in all aspects of the intervention, as they did not know which group they would be 




sessions with an interventionist.  During these sessions they received information about 
physical activity, weight loss, and dietary changes.  This group increased their fitness 
even though they did not receive any additional pieces of the intervention.  Importantly, 
the advice-only control group also lost weight.   Because increasing aerobic fitness was 
an important mediator between treatment status and follow-up Metabolic Syndrome, and 
weight loss was an important mediator between aerobic fitness and follow-up Metabolic 
Syndrome, it is reasonable that the treatment status had no significant impact on 
Metabolic Syndrome prevalence at either follow-up.  Further, our measurement of 
variables may have introduced some error.  The zero sphygmomanometer, while being 
the current “gold standard” in blood pressure measurement, has been shown to give a 
lower reading of 1 to 3 mmHg of both systolic and diastolic blood pressure when 
compared with the mercury sphygmomanometer (Gillman and Cook, 1995).  Due to 
randomization, any error introduced by this instrument should have been equally 
distributed among participants.  Stage 2 heart rate was used as a predictor of fitness.  
Although heart rate and VO2max are highly correlated (r=0.90) (ACSM, 2006), a 
maximal VO2 test was not conducted.  We also lost 146 participants due to missing 
follow-up fitness tests, which may have biased the results. 
Our findings have great public health importance as they show that Metabolic 
Syndrome can be prevented and reversed in males and females as well as African 
Americans and non-African Americans by improving aerobic fitness.  Importantly, these 
results can be maintained long-term as long as aerobic fitness levels remain elevated 
above baseline levels.  The prevalence decreased from well above the national average of 




months.  In conclusion, it is crucial to implement health promotions aimed at improving 
aerobic fitness in order to reduce the prevalence of Metabolic Syndrome, especially in a 
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